Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients
A Non-Interventional, Modified Delphi Study to Establish Consensus Recommendations on the Optimal Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients in South Korea
1 other identifier
observational
23
1 country
1
Brief Summary
The purpose of this study is to establish an expert consensus recommendations on managing patients with mHSPC in South Korea, and to provide clinicians with a comprehensive guide to support their clinical decision making. There are no secondary objectives for this study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jul 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 5, 2024
CompletedFirst Posted
Study publicly available on registry
June 11, 2024
CompletedStudy Start
First participant enrolled
July 10, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 29, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 29, 2024
CompletedNovember 21, 2024
November 1, 2024
19 days
June 5, 2024
November 19, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Treatment plans for patients with mHSPC
Treatment plans for patients with mHSPC within the local healthcare environment will be collected via online surveys and a consensus meeting will be held if required.
Up to 7 days
Study Arms (1)
Urologists
Health care professionals/panelist.
Interventions
No investigational drug will be administered to participants in this study.
Eligibility Criteria
Target recruitment of 25 urologists will be recruited with an acceptable goal of 20 as panelists from university hospitals in South Korea.
You may qualify if:
- Urologist from university hospitals in South Korea.
- Has a minimum 10 years of practice experience (experience as a military or public health doctor could be considered practice experience)
- Sees a minimum of 50 mHSPC patients in a year.
- At least 10 publications in SCIE (Science Citation Index Expanded) journals in the past 5 years.
You may not qualify if:
- Urologist in private practice.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
KR82001
Seoul, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Medical Director
Astellas Pharma Korea, Inc.
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 5, 2024
First Posted
June 11, 2024
Study Start
July 10, 2024
Primary Completion
July 29, 2024
Study Completion
July 29, 2024
Last Updated
November 21, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share
Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.